Targets › JAK
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on JAK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | LY2784544 JAK inhibitor | JAK | Phase 2 | Neoplasms, Hematologic | Dec 2026 |
| Renmin Hospital of Wuhan University | Ivarmacitinib Sulfate JAK/STAT signaling inhibitor | JAK | Phase 2 | Refractory Metastatic Colorectal Cancer | Dec 2027 |
Refractory Metastatic Colorectal Cancer (1) Neoplasms, Hematologic (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.